Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
DOV-216,303
Другие языки:

    DOV-216,303

    Подписчиков: 0, рейтинг: 0
    DOV-216,303
    DOV-216,303.svg
    Legal status
    Legal status
    Identifiers
    • 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    ChEMBL
    Chemical and physical data
    Formula C11H11Cl2N
    Molar mass 228.12 g·mol−1
    3D model (JSmol)
    • C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl
    • InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2 ☒N
    • Key:BSMNRYCSBFHEMQ-UHFFFAOYSA-N ☒N
     ☒NcheckY (what is this?)  (verify)

    DOV 216,303 is an experimental antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004; Merck and DOV terminated their relationship in December 2006.

    It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is the racemic mixture of amitifadine (DOV-21,947) and its (–)-enantiomer, DOV-102,677. Its IC50 values for SERT, NET, and DAT are Ki 14 nM, 20 nM, and 78 nM, respectively.

    As of March 2008, DOV had no intention to further develop DOV-216,303 because the patent on the compound had expired.

    In a mouse model, DOV-216,303 has shown the ability to promote recovery after spinal cord contusion.

    See also


    Новое сообщение